One of the underlying mechanisms of this inhibition involves the suppression of cancer cell proliferation through the inhibition of the insulin-like growth factor 1 receptor (IGF-1R)/AKT signaling pathway and the subsequent activation of the phosphatase and tensin homolog (PTEN)–eukaryotic initiation factor 2α (eIF2α) axis [64]. The gene discussed is AKT1; the disease is cancer.